Vir Biotechnology Q2 2026 earnings: Astellas revenue drives a return to profit

Vir Biotechnology (Nasdaq: VIR) reported Q2 2026 revenue of $238.9 million, up from $1.2 million a year earlier, and diluted EPS of $0.47, compared with a loss of $0.80. Net income reached $80.1 million versus a $111.0 million loss, primarily because the company recognized revenue associated with its Astellas collaboration. Cash, cash equivalents and investments ended the quarter at approximately $1.01 billion.

Core financial results

The quarter’s return to profitability was driven by $238.9 million of license and collaboration revenue, almost all of Vir’s reported revenue. Operating expenses also increased, but the collaboration-related revenue was large enough to produce $73.5 million of operating income.

R&D expense rose because of a $48.0 million milestone payment to Sanofi and higher manufacturing costs for the chronic hepatitis delta program. SG&A increased mainly due to one-time advisory and legal fees associated with closing the Astellas agreement.

Astellas collaboration reshaped earnings and liquidity

Vir received a $240.0 million upfront payment and a $75.0 million equity investment payment from Astellas during the quarter. It recognized $238.9 million of license and collaboration revenue in connection with the upfront payment, making the transaction the main reason for the swing from a loss to a profit.

The agreement also generated costs. A $48.0 million payment to Sanofi was included in the quarter’s cash movements and cited as a major driver of higher R&D expense, while transaction-related advisory and legal fees increased SG&A.

Cash, cash equivalents and investments increased by approximately $198.5 million during Q2 to about $1.01 billion. Because the reported profit was tied primarily to collaboration revenue rather than recurring product sales, the quarter’s earnings should be viewed in the context of the Astellas transaction.

Pipeline and clinical progress

Vir’s chronic hepatitis delta program remains its most advanced clinical asset. Complete Week 96 results from the Phase 2 SOLSTICE trial showed that 88% of participants receiving elebsiran plus tobevibart achieved undetectable HDV RNA, compared with 53% receiving antibody monotherapy. A last-observation-carried-forward analysis produced a 97% rate for the combination regimen.

The company said treatment-emergent adverse events were generally mild to moderate and transient, with no treatment-related serious adverse events or discontinuations. However, these Phase 2 findings still need validation through the ECLIPSE registrational program.

All three ECLIPSE trials are now fully enrolled. Vir expects topline data from Phase 3 ECLIPSE 1 in Q4 2026, followed by ECLIPSE 2 and ECLIPSE 3 results in Q1 2027.

In oncology, Vir and Astellas closed their global collaboration for prostate cancer candidate VIR-5500. Vir initiated additional Phase 1 monotherapy and combination dose-expansion cohorts and expects to add cohorts combining VIR-5500 with docetaxel and darolutamide. The company anticipates starting pivotal Phase 3 trials in 2027.

Vir also expects updated Phase 1 dose-escalation data for HER2-targeted VIR-5818 in the second half of 2026. Enrollment continues in the Phase 1 study of EGFR-targeted VIR-5525.

Financial guidance

Vir’s quantitative financial outlook focused on liquidity. Based on its current operating plans, including the net effects of the Astellas collaboration, the company expects its available cash and investments to fund operations into the second half of 2028.

This runway covers several scheduled clinical milestones, but actual duration will depend on trial costs, manufacturing spending and the pace of oncology development.

Recent insider transactions

The supplied insider records include three recent open-market sales with dates, prices and transaction amounts. These transactions are presented without inferring insiders’ views about Vir’s prospects.

The broader transaction list also contained director stock awards, but the supplied records did not provide award share quantities. Over the reported six-month period, insiders recorded 581,377 shares of purchases and awards across 13 transactions and 261,395 shares of sales across 19 transactions, resulting in net additions of 319,982 shares.

Risks investors need to watch

• Earnings depend on collaboration accounting: Q2 profitability was primarily attributable to revenue recognized from the Astellas upfront payment, so future results may vary substantially without comparable collaboration revenue.
• Phase 3 validation remains essential: The SOLSTICE data support the chronic hepatitis delta program, but ECLIPSE results will be more important for the potential regulatory filing package.
• Development and manufacturing costs are rising: R&D expense increased due to the Sanofi payment and commercial-readiness manufacturing work, while additional oncology cohorts and planned pivotal trials require further spending.
• Oncology execution involves partnership and trial-design risk: VIR-5500 remains in Phase 1, and the planned 2027 Phase 3 program depends on data from ongoing monotherapy and combination cohorts.

Summary

Vir’s Q2 2026 profit and higher cash balance were principally products of the Astellas collaboration, while underlying clinical development spending continued to rise. The next major test is operational rather than accounting-related: ECLIPSE 1 data in Q4 2026, followed by ECLIPSE 2 and 3 results in Q1 2027, will help determine whether the chronic hepatitis delta program can support a global regulatory package.